about
Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursPopulation pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry.Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.Population pharmacokinetic study of memantine: effects of clinical and genetic factors.Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.Dosage optimization of treatments using population pharmacokinetic modeling and simulation.Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologiquePharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individualsInfluence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIVPopulation Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
P50
Q34058351-66A1BAE2-D011-4ADC-9D85-7E56248A68D8Q34209573-6E11BE0B-B886-4CA3-998F-CF3D30C220F7Q34570930-D3944472-BA29-4B18-9FB7-81E1EF61F480Q36558437-E3451B84-73E2-4B0E-8B11-913FA0CA6E20Q36729934-4058226E-5EF6-48E8-8DDC-CC53CEDDD540Q37038270-21E72D39-D2BC-413D-A83B-24F2D00F9B66Q37538683-79C1CC18-EF99-43F5-8854-F7E9824DFD19Q40735151-234D1A51-6525-46B2-BAE7-7A4B13B89CB5Q40780592-DC093A7E-8ED3-4018-826F-038C0F6C4AE7Q41639978-85E2108C-5B02-4D1C-AC4B-AF5CBAE64DA0Q42205826-37F33204-11AF-4421-BA24-8031EC6DD3E5Q42215539-404AB86A-CF6A-4AFC-9C43-14CAD32D6E9FQ43752615-CC2CC263-A211-4B0F-BC76-CC55B283DC75Q44337894-8F0B4277-D6F4-4FEE-BD92-99DC28D88596Q51336587-438A8E22-1143-4795-AF4E-C3F7A91203C6Q53815605-8683A54A-871F-44D3-87E9-234BBBA2C4F4Q56379721-908153AD-F11C-47A7-9895-E640B6B15DA3Q57226039-33BE80D8-D637-4C29-8823-6D430E97CE34Q91846901-D6BDF709-E578-437B-A84F-551AFCB48E02Q91869819-2B022FB7-FB99-46D6-83E3-F047DA74D8FB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Monia Guidi
@ast
Monia Guidi
@en
Monia Guidi
@es
Monia Guidi
@nl
type
label
Monia Guidi
@ast
Monia Guidi
@en
Monia Guidi
@es
Monia Guidi
@nl
prefLabel
Monia Guidi
@ast
Monia Guidi
@en
Monia Guidi
@es
Monia Guidi
@nl
P106
P1153
55260015800
P31
P496
0000-0002-6419-9317